Hospital da Senhora da Oliveira, Guimarães EPE

Guimarães 4835-044

1 studies enrolling now · 3 studies all time

What they study most

Gastric Cancer, Gastroesophageal Junction Cancer, HER2-Positive Primary Breast Cancer, Residual Invasive Breast Cancer, Ulcerative Colitis

Studies at this site

• Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer — Recruiting now
• A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05) — Running, not enrolling
• Phase 2 Dose-finding IMU-838 for Ulcerative Colitis — Stopped early